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Abstract: Monoclonal antibody G250 (mAbG250) recognizes a determinant on carbonic 
anhydrase IX (CAIX). CAIX is expressed by virtually all renal cell carcinomas of the clear 
cell type (ccRCC), but expression in normal tissues is restricted. The homogeneous CAIX 
expression in ccRCC and excellent targeting capability of mAbG250 in animal models led 
to the initiation of the clinical evaluation of mAbG250 in (metastatic) RCC (mRCC) 
patients. Clinical studies confirmed the outstanding targeting ability of mAbG250 and 
cG250 PET imaging, as diagnostic modality holds great promise for the future, both in 
detecting localized and advanced disease. Confirmation of the results obtained in the  
non-randomized clinical trials with unmodified cG250 is needed to substantiate the value 
of cG250 treatment in mRCC. cG250-Based radio immuno-therapy (RIT) holds promise 
for treatment of patients with small-volume disease, and adjuvant treatment with unmodified 
cG250 may be of value in selected cases. In the upcoming years, ongoing clinical trials 
should provide evidence for these assumptions. Lastly, whether cG250-based RIT can be 
combined with tyrosine kinase inhibitors, which constitutes the current standard treatment 
for mRCC, needs to be established. 
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1. Introduction 
Renal cell carcinoma (RCC) accounts for approximately 3% of all cancers and was estimated to be 
diagnosed in over 60,000 individuals in the United States in 2011 [1]. The most prominent subtype of 
RCC (~70%) is clear cell (ccRCC). In approximately 70% of patients, the tumor is confined to the 
kidney at presentation. In 30% of cases, patients present with or develop metastases at a later time 
point. Patients with advanced disease have a poor prognosis with an overall five-year survival of 
<10%. Based on the molecular insight that ccRCC is characterized by molecular aberrations that leads 
to high expression levels of amongst others VEGF, various anti-angiogenic therapies have been 
developed. For patients with metastatic RCC (mRCC), several anti-angiogenic therapies are  
available [2–7] Implementation of these new treatment modalities has led to a significant increase in 
progression-free survival [8]. However, complete responses (CR) are rare, and long-lasting stable 
disease (SD) is often seen, but eventually all patients progress. Moreover, frequently significant 
toxicity can occur, which may lead to drug cessation or dose reduction.  
Monoclonal antibody G250 (mAbG250) was isolated more than 25 years ago from a hybridoma 
produced from a splenocyte of a mouse immunized with a fresh human RCC [9]. Immunohistochemical 
analysis of renal tumors showed homogeneous expression in the vast majority (>80%) of primary RCC 
and about 70% of mRCC lesions. Analyses of non-RCC tumors revealed variable, non-homogeneous 
staining. Initial specificity analysis on normal human tissues revealed cross-reactivity with gastric 
mucosal cells and large bile ducts. Subsequent in-depth fine-specificity analysis revealed reactivity 
with epithelial cells of the upper gastrointestinal tract and pancreatic cells. Originally, no association 
with a particular histological RCC subtype was noted, but it is now clear that the antigen recognized by 
mAbG250 is almost ubiquitously expressed in ccRCC [10,11]. Based on this fine-specificity analysis, 
mAbG250 target antigen was readily suggested as a potential diagnostic and therapeutic target. 
2. Cloning of G250 Antigen and Relation to ccRCC 
The general occurrence of the antigen recognized by mAbG250 in RCC and absence from normal 
kidney suggested that the aberrant expression was inherently related to tumor development, possibly 
due to a common initiating event [9].  
Cloning of the antigen recognized by mAbG250 showed that mAbG250 recognized a 
conformational determinant of carbonic anhydrase IX (CAIX), a gene originally identified in HeLa 
cells [12,13]. CAIX is a member of the carbonic anhydrase group of enzymes, has a transmembrane, as 
well as a cytosolic domain, and catalyzes the reaction: CO2 + H2O↔HCO3− + H+. Extensive molecular 
studies of the CAIX promoter region demonstrated that HIF-1α binding was an absolute requirement 
for CAIX expression in ccRCC [14]. This finding uncovered a direct molecular link between the 
observed ccRCC-specificity of mAbG250 and the molecular events leading to ccRCC. Elegant 
molecular studies in families suffering from Von Hippel-Lindau (VHL) syndrome, an autosomal 
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dominant disease, showed that defects in the VHL gene were responsible for tumor development. 
These patients develop multiple tumors, including ccRCC. Studies in sporadic ccRCC demonstrated 
that also in these cases, VHL was mutated [15]. Subsequent studies showed that VHL is involved in 
the hypoxic response: under normoxic conditions, hypoxia-inducible factor-1α (HIF-1α) is 
hydroxylated by prolyl hydroxylase domain proteins and bound by pVHL, catalyzing the 
polyubiquitylation of prolyl hydroxylated HIF-1α for subsequent degradation via the 26S  
proteasome [16,17]. If pVHL is mutated, as in ccRCC, binding of HIF-1α by pVHL does not occur; 
the unbound HIF1α is not degraded, but associates with the constitutively stable partner HIF-1β to 
form an active heterodimeric HIF-1 transcription factor, which binds to hypoxia-responsive elements 
located in the promoter/enhancer regions of numerous hypoxia-inducible genes. In view of the HIF-1α 
dependency of CAIX expression, the ubiquitous expression of the G250/CAIX antigen could be 
explained straightforwardly by nonfunctional VHL gene product in ccRCC (Figure 1). 
Elucidation of the molecular pathway of CAIX gene expression also readily explained the 
heterogeneous staining pattern in non-RCC tumors: this is the consequence of local hypoxia, leading to 
HIF-1α stabilization and subsequent G250/CAIX expression. In fact, G250/CAIX is now regarded as 
an appropriate substitute hypoxia marker in various tumor types [18,19].  
Figure 1. Schematic representation of regulation of carbonic anhydrase IX expression 
(CAIX) in kidney. In normal kidney tissue, hypoxia inducible factor-1α (HIF-1α) is 
hydroxylated by prolyl hydroxylase domain proteins (PHD) and bound by Von  
Hippel-Lindau protein (pVHL). Subsequently, the complex is ubiquitinated, which causes 
degradation of HIF-1α. In clear cell renal cell carcinoma (ccRCC), pVHL is mutated and 
binding with HIF-1α is prohibited. Subsequently HIF-1α forms a heterodimeric complex 
with HIF-1β, translocates to the nucleus, where it activates hypoxia inducible genes, such 
as vascular endothelial growth factor and CAIX, which is expressed on the tumor cell 
membrane. Reproduced with permission from Stillebroer et al., European Urology, 
published by Elsevier, July, 2010; 58(1): 75–83 [20]. 
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3. Clinical Studies with mAbG250 
3.1. Imaging Studies 
The incidental detection of renal lesions has increased up to 50% by improved radiologic imaging, 
such as contrast enhanced CT and positron emission tomography (PET) with fluorine-18 
fluorodeoxyglucose (18F-FDG) [21,22]. With increased possibilities for nephron-sparing surgery and 
the realization that around 20% of these masses are benign tumors, 25% are indolent tumors with 
limited metastatic potential and 54% represent the more potentially malignant ccRCC, it has become 
important to differentiate between these entities. However, conventional techniques have difficulties in 
differentiating between benign and malignant renal lesions. Therefore, surgical interventions are 
performed that could have been prevented. Consequently, new imaging techniques are needed to 
improve the differentiation between benign and malignant renal lesions. In view of the ccRCC 
specificity of mAbG250, multiple studies have addressed its ccRCC targeting capabilities.  
Since its discovery, numerous preclinical targeting studies were performed in various mouse  
models [23–26] with various radionuclides, as well as in ex vivo perfusion experiments in tumor-bearing 
kidneys [27] with mAbG250. Selective and extraordinary high uptake of murine mAbG250 (mG250) 
in antigen-positive tumor xenografts was observed (e.g., up to more than 100% of the injected dose per 
gram tumor tissue at the lowest protein doses (up to 1 µg)). The combination of the restricted 
G250/CAIX expression in normal tissues, homogeneous G250/CAIX expression in RCC and excellent 
targeting capability in animal models provided a solid basis for the initiation of the clinical evaluation 
of mG250 in patients to investigate the possibility to use CAIX imaging as a new diagnostic tool. 
The first clinical study with mouse mAbG250 (mG250) concerned a phase I presurgical protein 
dose-escalating study of 131I-mG250 conducted to determine tumor uptake and mG250 distribution in 
patients suspect for RCC [28]. Apart from clear visualization of primary and metastatic (known and 
occult) RCC at protein doses >2 mg, occult metastases were imaged, immediately demonstrating the 
diagnostic potential. Levels of mG250 in tumor tissue samples reached levels of up to 0.1% of the 
injected dose per gram of tumor (%ID/g), these levels being among the highest reported in studies of 
solid tumors. Additionally, normal tissue uptake, actually limited to the liver, was saturable, 
encouraging future development of mG250 in RCC. Because histological confirmed CAIX-negative 
tumors did not image, it was concluded that mAbG250 accumulation was CAIX-specific. Since 
administration of murine G250 led to the formation of human-anti-mouse-antibodies (HAMA) in all 
patients, preventing multiple administrations [29], a chimeric variant of G250 (cG250) was constructed 
(see Table 1).  
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Table 1. Overview of Imaging studies with mAbG250 in RCC patients. 
Ref. Year Agent 
Number of 
patients 
Patients Outcome # Remarks 
Oosterwijk et al. [28] 1993 131I-mG250 15 Primary RCC 12/12 pts Phase I, dose escalation 
Steffens et al. [30] 1997 131I-cG250 16 Primary RCC 13/13 pts Phase I, dose escalation 
Steffens et al. [31] 1999 
131I-cG250 &  
111In-cG250 
10 Primary RCC 10/10 pts Dual label study 
Brouwers et al. [32] 2002 
131I-cG250 vs.  
18F-FDG 
20 M + RCC 
131I-cG250: 34/112 lesions 
18F-FDG: 77/112 lesions 
Comparative intrapatient study 
Brouwers et al. [33] 2003 
131I-cG250 &  
111In-cG250 
5 M + RCC 
111In-cG250: 47 lesions  
131I-cG250: 30 lesions 
Comparative intrapatient study 
Divgi et al. [34] 2007 124I-cG250 26 Primary RCC 15/16 ccRCC imaged Prospective cG250-immunoPET 
Divgi et al. [35] 2013 124I-cG250 226 Primary RCC 
124/143 ccRCC imaged  
(sens. & spec. 86%) 
Phase III, REDECT trial 
Muselaers et al. [36] 2013 111In-cG250 29 Primary RCC 15/16 ccRCC imaged 111In-cG250 immunoSPECT 
# outcome refers to diagnostic accuracy, i.e., number of positive images over total number of images mG250: mouse monoclonal antibody G250; cG250: chimeric 
monoclonal antibody G250; ccRCC: clear-cell renal cell carcinoma; 18F-FDG: fluorine-18 fluorodeoxyglucose; M + RCC: metastatic renal cell carcinoma; PET = positron 
emission tomography; SPECT: single-photon emission CT; sens.: sensitivity; spec.: specificity. 
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Because chimerization might lead to altered pharmacokinetic and pharmacodynamic behavior, a 
phase I protein dose-escalation trial of 131I-cG250 identical to the phase I mG250 protein dose-escalation 
trial was necessary [30]. All patients with an antigen-positive tumor (n = 13) showed excellent 
targeting of radioactivity to all known tumor sites. Similar to mG250, previously undetected metastatic 
lesions (brain, bone and soft tissue) were detected. An example of the excellent cG250 uptake is shown 
in Figure 2. The performance of the chimerized G250 mAb was almost identical to the mouse 
mAbG250, including the optimal protein dose (5–10 mg) and very high focal uptake (up to  
0.52% ID/g). The half-life (t½ β) of cG250 was comparable to mG250 (68.5 h vs. 47 h). 131I-cG250 
uptake in non-tumor tissues remained low. Most importantly, chimerization greatly diminished the 
immunogenicity of the antibody: in only two of 15 patients, low levels of human anti-chimeric 
antibody (HACA) were observed [30]. Thus, multiple administrations became feasible.  
Figure 2. Whole body scan of a patient with multiple RCC metastases two weeks after 
infusion of 4144 MBq 131I-cG250. Ant.: Anterior view; Post.: Posterior view. Note: 
thyroid uptake is due to non-specific accumulation, despite attempts to block thyroid 
uptake with intake of saturated potassium iodine. 
 
Although very high uptake levels were observed, locally, cG250 tumor uptake was heterogeneous; 
this heterogeneity could not be explained by antigen expression alone. No consistent association with 
necrosis or vasculature was noted [37]. Since highly dynamic vascularization and intratumoral blood 
flow may contribute to this heterogeneous tumor uptake, the impact of time on tumor uptake of cG250 
was studied in a clinical setting. In this dual-label study, ten patients with a clinical diagnosis of 
primary RCC received two independent consecutive administrations of cG250, separated by four days. 
Post-surgery, the distribution of both administrations was mapped and analyzed. The study 
demonstrated that cG250 distribution did not differ between different administrations, indicating that 
intrinsic tumor factors, such as internalization and local differences in interstitial fluid pressure, played 
a prominent role in intra-tumoral heterogeneity of antibody distribution [31]). Initially, this explanation 
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was felt to be improbable, because 131I-cG250 tumor retention in patients was in the order of weeks, 
suggesting very low internalization rates [29].  
To compare 131I-cG250 radioimmunoscintigraphy (RIS) with 18F-FDG PET, 20 mRCC patients 
were scanned using both techniques. Routine imaging modalities, performed before the experimental 
imaging techniques, revealed 79 metastases in these 20 patients. 18F-FDG PET and 131I-cG250 scintigraphy 
revealed 33 previously unknown lesions, of which 32 were PET positive and seven cG250-positive. 
Remarkably, 131I-cG250 RIS detected only 30% (34/112) of documented metastases, whereas with  
18F-FDG PET, 69% (77/112) were detected [32]. The low percentage of RCC metastases detected by 
cG250-RIS in this study contrasts with the results of many other studies, where excellent visualization 
of all known metastases occurred and often new lesions were visualized, which were not seen using 
conventional imaging techniques. The inferiority of 131I-cG250 RIS in detecting metastases might have 
been due to internalization of the radiolabeled mAb and subsequent excretion of 131I by the tumor 
cells. Internalization and translocation of mAbG250 to the endocytic recycling compartment in vitro 
has been described before [38]. Alternatively, it is possible that many lesions were CAIX-negative,  
albeit that, in general, approximately 75% of ccRCC metastases are high in CAIX expression [39]. 
Unfortunately, we were unable to determine the CAIX expression in this trial, since lesions  
were unavailable. 
The dual label clinical trial suggested that cG250 can be internalized by G250 antigen-expressing 
RCC cells. Indeed, follow-up animal experiments demonstrated that internalization can occur [40] and 
that accumulation in tumors of cG250 labeled with residualizing radionuclides, such as 111In, might be 
higher than that of non-residualizing 131I [25,41]. To investigate this phenomenon in detail in patients 
with RCC, a dual-label study was performed, with cG250 labeled with the residualizing radionuclide 
111In and non-residualizing radionuclide 131I [33]. Four days post injection, the 111In-cG250 images 
revealed more metastatic lesions (n = 47) than 131I-cG250 (n = 30). Moreover, quantitative analysis of 
25 metastases showed higher activities of 111In-cG250 than of 131I-cG250 in 20 of 25 lesions, thus 
111In-cG250 outperformed 131I-cG250 for visualization of metastatic RCC lesions. This was partly due 
to the superior gamma camera characteristics of 111In, but mainly because higher tumor:blood ratios 
were obtained.  
ImmunoPET—that is, PET scanning that combines the favorable characteristics of PET  
(higher spatial resolution, three-dimensional imaging and superior quantitative analysis of images) 
with cG250—seems ideal for RCC imaging. However, the most commonly used positron emitters  
(11C and 18F) cannot be combined with the relatively slow pharmacokinetics of intravenously injected 
radiolabeled mAb (optimal tumor uptake after several days), because of their too-short half-lives  
(2 min to 1.8 h). On the other hand, the positron emitters, 89Zr and 124I (half-lives 78 and 100 h, 
respectively), seem to be good candidates to match these slow kinetics. In the first cG250 immunoPET 
study, 124I-cG250 (185 MBq, 10 mg) was evaluated in 26 patients with suspect renal masses to study 
whether ccRCC could be recognized unequivocally. In 15/16 patients with histological confirmed 
ccRCC after surgery, positive images were obtained (one patient received nonreactive antibody, due to 
technical problems). In addition, all nine non-clear cell renal masses were negative; hence, the 
sensitivity and specificity of 124IG250 PET for ccRCC was 94% and 100%, respectively. The negative 
(NPV) and positive predictive value (PPV) were 90% and 100%, respectively [34].  
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This proof of principle study suggested that immunoPET might help in clinical decision-making 
and might aid in the surgical management of patients with small renal masses scheduled for  
partial nephrectomy. 
To substantiate whether cG250 immunoPET might be helpful in the clinical management of 
patients with suspect renal masses, a large multicenter phase III trial comparing 124I-cG250 immuno 
PET/computed tomography (CT) (124I-Girentuximab/REDECTANE®) scanning to contrast enhanced 
CT (CECT) for the detection of ccRCC was performed. In total, 226 patients scheduled for partial or 
complete nephrectomy were enrolled in this study [35]. 124I-girentuximab was well tolerated, and 195 
patients were evaluable. The results of this trial confirmed the high specificity and sensitivity of  
124I-cG250 for ccRCC. Notably, the average sensitivity and specificity were higher for G250 PET/CT 
than for CECT (86.2% vs. 75.5% and 85.9% vs. 46.8%, respectively). The authors concluded that  
124I-girentuximab PET/CT can accurately and noninvasively identify ccRCC, with potential utility for 
designing best management approaches for patients with renal masses. One limitation of 124I-based 
immunoPET is the limited availability of 124I worldwide, requiring centralized production. 
Because girentuximab labeled with the gamma-emitting radionuclide indium 111In is easier to 
produce as an off-the-shelf agent, not requiring centralized production nor specialized equipment, and 
because dual labeling studies showed superior imaging of 111In-cG250 in mRCC [33], we investigated 
this agent as a potential imaging modality. Similar to 124I-girentuximab immunoPET, single-photon 
emission CT (SPECT) with 111In-labeled girentuximab is non-invasive and does not require the use of 
intravenous contrast agents, which makes it suitable for patients with an impaired renal function. In 
this study, 29 patients with an incidentaloma of the kidney or having a history of ccRCC with lesions 
on follow-up imaging suspect for metastases were enrolled [36]. Distinct uptake of 111In-girentuximab 
was seen in 16 of 22 patients presenting with a renal mass (Figure 3). All renal masses proven to be 
ccRCC after resection (n = 15) were detected with 111In-girentuximab. In one of the 16 patients, a type 
2 papillary RCC with histological proven CAIX expression was targeted with 111In-girentuximab. In 
addition, no targeting was observed in six patients. Histopathological evaluation in 4/6 patients 
revealed two cases of benign oncocytoma, a chromophobe and a mucinous tubular spindle cell 
carcinoma subtype tumor. For the two remaining patients, biopsy material was unavailable, but close 
monitoring with repeated CT scans did not reveal growth of the suspected mass in the follow-up period 
(>24 months). In this limited group of patients, the PPV of 111In-girentuximab imaging for ccRCC was 
94%. In addition, seven patients with a history of ccRCC and possible metastatic lesions on follow-up 
computed tomography scans were imaged with 111In-girentuximab. In 4/7 patients, the lesions showed 
preferential uptake of 111In-girentuximab and local or systemic treatment was initiated. In three other 
cases, no targeting was seen. During follow-up of these three patients, 1/3 showed progression, for 
which systemic treatment was started. In conclusion, cG250 immunoSPECT either labeled with 124I or 
with 111In can be used to detect ccRCC lesions in patients with a primary renal mass and to clarify the 
nature of lesions suspect for metastases in patients with a history of ccRCC.  
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Figure 3. Images of a patient with metastatic RCC. Conventional CT (A) and  
111In-girentuximab immunoSPECT (B) images of a patient with metastatic ccRCC. Clear 
and preferential uptake of the radiolabeled antibody was observed in mediastinal and pleural 
lesions (arrows). The patient was enrolled in the phase II 177Lu-girentuximab RIT trial. 
3.2. Therapy Studies 
The therapeutic potential of CAIX targeting with mAbG250 has been studied in numerous clinical 
trials (see Table 2). Roughly, these can be divided into trials with “naked” antibody alone or in 
combination with cytokines and radioimmunotherapy trials. 
In the first dose escalating radioimmunotherapy (RIT) trial, 131I-mG250 was administered to 
progressive patients with measurable, histological proven ccRCC [29]. In this trial, hepatic toxicity 
was observed, most likely the result of specific mG250 accumulation in the liver. Indeed, with higher 
doses, the liver uptake was decreased, suggesting saturation of G250 sites by the antibody. The toxicity 
was transient and not dose-limiting. As in all RIT studies with radiolabeled antibodies, dose-limiting 
toxicity (DLT) was hematopoietic. After determining the maximum tolerated dose (MTD) of  
131I-activity (3330 MBq/m2), 15 patients were treated at the MTD level to determine efficacy, but no 
major responses were noted. However, overall survival of patients treated with 131I-mG250 seemed to 
be increased in comparison with that of historic control patients: 17/33 SD and two minor responses. 
As mentioned earlier, the development of high HAMA levels in all patients precluded retreatment, and 
all subsequent trials were carried out with cG250. 
Following the protein dose-escalation trial with 131I-cG250, which established the most favorable 
protein dose, a phase I 131I-cG250 activity dose escalation was performed to establish DLT similar to 
the mG250 trial [42]. One major adjustment was the inclusion of an imaging dose (222 MBq of 131I- 
labeled to 5 mg of cG250), before being allowed to advance to therapeutic dose (1665–2775 MBq of 
131I- labeled to 5 mg of cG250) to prevent infusion of high-dose 131I-cG250 in CAIX-negative patients. 
Int. J. Mol. Sci. 2013, 14 11411 
 
Table 2. Overview of Therapy studies with mAbG250 in RCC patients. 
Ref. Year Agent 






Divgi et al. [29] 1998 131I-mG250 33 M + RCC 17 SD; 16 PD 2–3 mo Phase I/II 
Steffens et al. [42] 1999 131I-cG250 12 M + RCC 1 PR; 1 SD; 10 PD 9+; 3–6 mo Phase I Activity dose 
Divgi et al. [43] 2004 131I-cG250 15 M + RCC 7 SD; 8 PD 2–11 mo Phase I fractionated dose 
Brouwers et al. [44] 2005 
131I-cG250 
Two doses 
27 M + RCC 5 SD; 22 PD 3–12 mo Phase I two high doses 
Stillebroer et al. [45] 2012 
177Lu-cG250 
Multiple doses 
23 M + RCC 1 PR; 17 SD 9+; 3+ mo Phase I dose escalation 
Davis et al. [46] 2007 cG250 12 M + RCC 1 CR; 8 SD; 3 PD 6–66 wk Phase I 
Bleumer et al. [47] 2004 cG250 36 M + RCC 
1 CR; 1 PR; 8 SD; 
26 PD 




High risk, after 
nephrectomy 
No benefit * 
 
Phase III 
Davis et al. [49] 2007 cG250 + IL-2 9 M + RCC 2 SD; 7 PD 6, 12 wk Phase I 
Bleumer et al. [50] 2006 cG250 + IL-2 35 M + RCC 1 PR; 7 SD; 27 PD 95+; 24+ wk Phase II 
Siebels et al. [51] 2011 cG250 + IFN-2α 31 M + RCC 1 CR; 9 SD 17+; 24+ wk Phase II 
* No benefit for whole population, high CAIX expression correlated with risk of recurrence reduction; mG250: mouse monoclonal antibody G250; cG250: chimeric 
monoclonal antibody G250; ccRCC: clear-cell renal cell carcinoma; M + RCC: metastatic renal cell carcinoma; IL-2: interleukin-2; IFN: interferon; CR: complete response; 
PR: partial response; SD: stable disease; PD: progressive disease; mo: months; wk: weeks. 
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Only those patients showing targeting to tumor (n = 8) received the therapeutic infusion of  
131I-cG250 one week later. Unexpectedly, through the administration of the scout dose, liver toxicity 
was avoided, most likely because the liver compartment was saturated. Alternatively, hepatic uptake of 
chimeric mAbG250 is lower than murine mAbG250. At equal doses, liver uptake of mG250 [28] was 
2–3-times higher than the liver uptake of cG250 [30]. Dose-limiting toxicity of 131I-cG250 was at  
2775 MBq 131I-cG250/m2, significantly lower than DLT observed for the murine version. The MTD 
was therefore set at 2220 MBq/m2. Almost certainly, the extended serum half-life is responsible for the 
enhanced hematopoietic toxicity, since this leads to extended radiation of the bone marrow compartment.  
In one patient, HACA was observed in the serum sample obtained prior to the injection of the 
radiolabeled antibody, as well as in subsequent serum samples. cG250 was rapidly cleared. The 
observed HACA was probably due to previous injections with mAbG250. This particular patient had 
participated four months beforehand in another clinical study and had received two injections of 
mAbG250, four days apart. Targeting of mAbG250 was observed in his primary tumor at that time. No 
HACA responses were detected in all other patients.  
An antitumor response was observed in 2/8 patients; one SD for 3–6 months and one partial 
response (PR) >9 months. Both patients were treated at the 2220 MBq/m2 dose level. However, quite 
disappointingly, all other patients showed progression of disease. 
This first RIT trial with cG250 clearly showed that increased doses of radioactivity to the tumors 
were required to achieve more complete and lasting responses. In an effort to increase RIT efficacy, a 
fractionated dose RIT was performed, based on whole-body radiation absorbed dose [43]. 
Fractionated RIT is more effective than a single large amount and is associated with a lower 
toxicity profile in animal models. The primary objective of this trial was to determine the maximum 
tolerated whole-body radiation-absorbed dose of fractionated 131I-cG250, with dose escalation referred 
to here as the escalation of average whole-body absorbed dose. Fifteen patients with measurable 
metastatic renal cancer were included. The majority of patients tolerated repeated injections with no 
change in kinetics, confirming the lack of immunogenicity of the antibody construct. Whole-body and 
serum kinetics varied significantly between patients, with estimated biologic clearance half-times 
ranging from 3.2 to 7.5 days for the whole body and from 1.3 to >5 days for serum β–half-life (t½ β). 
In two of 15 patients, HACA was observed, which lead to a faster serum clearance. Similar to single dose, 
cG250 RIT, DLT was hematopoietic. In this logistically demanding fractionated administration 
regimen, sparing of the hematopoietic system was not observed. Moreover, the total dose that could be 
delivered was low, and efforts along these lines were abandoned.  
In view of the minimal clinical response in single doses cG250 RIT, a study was performed with 
two sequential high-dose (at MTD) 131I-cG250 treatments in patients with progressive mRCC [44]. 
After receiving a scout dose of 185 MBq/m2 of 131I-cG250 to demonstrate tumor targeting, 29 patients 
with adequate cG250 uptake received a therapeutic dose of 2220 MBq/m2 131I-cG250. In the absence 
of grade 4 hematological toxicity, patients received a second cycle after three months, consisting of a 
diagnostic infusion and a second high dose injection of 131I-cG250, escalated from 1110 MBq/m2 to 
1665 MBq/m2. The MTD of the second RIT was 1665 MBq/m2, with myelotoxicity as DLT. Four 
patients were excluded from the study, because they developed HACA after the first RIT dose (n = 2), 
after the second scout dose (n = 1) or after the second RIT dose. Those patients developed high HACA 
titers with enhanced clearance of injected mAbG250 (t½ β: 20–27 h). In an additional four patients, 
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detectable HACA titers at low levels developed in the course of the study. In these patients, no 
enhanced clearance was observed (t½ β: 52–74 h). Of the 16 patients who completed the protocol at 
both MTDs, none demonstrated an objective response, but five previously progressive patients had 
stabilization of their disease lasting 3–12 months. The low efficacy was partly attributed to the bulky 
disease in these end-stage patients, as sufficiently high radiation doses of 131I could not be delivered to 
these large tumor masses. An inverse correlation between the size of metastases and radiation-absorbed 
dose was observed, and dosimetric analyses showed that therapeutic radiation doses (>50 Gy) were 
only guided to lesions smaller than 5 g. Therefore, it was suggested that future RIT with cG250 should 
aim at treatment of small-volume disease or should be used in an adjuvant setting, or other more potent 
radionuclides should be used [52]. 
Preclinical animal studies performed with cG250 labeled with more potent radionuclides (177Lu, 90Y 
or 186Re) for RIT showed that tumor growth was most effectively inhibited by 177Lu-cG250, followed 
by 90Y-, 186Re- and 131I-cG250 [41]. Metabolites labeled with metallic radionuclides, such as  
111In, 90Y and 177Lu, are trapped in the lysosomes and residualize after internalization of the  
mAb–antigen complex by the target cells. Intracellular 131I-cG250 is metabolized, and tyrosine-131I is 
rapidly excreted by the tumor cell upon internalization. These RIT studies clearly showed the 
superiority of 177Lu- and 90Y-based RIT, in line with other studies. The dual-label study discussed 
before [33] also supported that trapped radionuclides are superior to the non-trapped iodine. In view of 
this evidence, subsequent clinical studies have focused on the possibility to use 90Y or 177Lu in RIT [53].  
Recently, the results of a phase I/II trial with 177Lu-cG250 were published [45]. This trial was 
paralleled by a trial with 90Y-cG250 at Memorial Sloan Kettering Cancer Centre, New York 
(clinicaltrials.gov/NCT00199875). In the 177Lu-cG250 trial, 23 patients with progressive mRCC with 
proven ccRCC received a diagnostic dose of 111In-cG250 (185 MBq), to establish adequate tumor 
accumulation followed by a dose of 177Lu-cG250 one week post 111In-cG250 injection (start dose  
1110 MBq/m2 177Lu, increments of 370 MBq/m2; three patients/dose level). In four patients, elevated 
HACA levels during treatment were observed. In two patients, these HACA levels precluded 
administration of a subsequent treatment cycle. In the absence of grade 4 toxicity, patients were 
eligible to receive a second (13/23) and a third cycle (4/23), at 75% of the dose level of the previous 
injection. Hematopoietic toxicity was dose-limiting, and MTD was set at 2405 MBq/m2, 111In-cG250 
images were superimposable on the 177Lu-cG250 images, illuminating the predictive value of  
111In-cG250 for 177Lu-cG250 accumulation [45]. In one patient, grade IV toxicity was observed at the 
1850 MBq/m2 dose level. No significant toxicity was observed in the other patients treated at MTD, 
also not after the second or third treatment cycle. The majority of patients responded by stabilization of 
disease. In one patient (1850 MBq/m2 dose level), a PR was documented that lasted for nine months. 
Dosimetric analyses indicated effective uptake after consecutive treatments. Observed hematologic 
toxicity, especially platelet toxicity, correlated significantly with the administered activity, whole-body 
absorbed dose and red marrow dose. The tumor-to-red marrow dose ratio was higher for RIT with 
177Lu-cG250 than for RIT with 90Y-cG250, indicating that 177Lu has a wider therapeutic window for 
RIT with cG250 than 90Y. The authors concluded that in patients with metastasized renal cell 
carcinoma, higher radiation doses can be guided to the tumors with 177Lu-cG250 than with  
90Y-cG250 [54]. The authors concluded that RIT with 177Lu-cG250, targeting CAIX, may stabilize 
previously progressive metastatic ccRCC. 
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3.3. Therapeutic Studies with Unmodified cG250  
Antibodies have the capacity to lyse cells by complement activation or by antibody-dependent 
cellular cytotoxicity (ADCC). In vitro studies established that cG250 could initiate cell lysis through 
ADCC of CAIX-positive cells [55,56]. Also, significant tumor growth reduction was noted when mice 
bearing human RCC xenografts were treated with naked mAbG250 [49]. Based on these results, a phase 1 
study with escalating doses of 5–50 mg/m2 of cG250 (Girentuximab/RENCAREX®), with weekly infusions 
for six6 weeks, was initiated. Treatment up to the highest dose was safe and well tolerated. Of the 11 
mRCC patients treated, one patient showed a CR and nine patients had SD after one treatment cycle [46]. 
In the subsequent phase 2 study, 36 patients with advanced RCC were included, all received 50 mg 
of cG250 weekly for 12 weeks. Before treatment, 80% of patients were progressive. After one 
treatment cycle, 28% of previously progressive patients had SD for at least six months, suggesting a 
clinical benefit [47]. During follow-up, one CR and one PR were noted, which lasted >1 year. The 
median survival of 15 months with 41% of the 32 evaluable patients still alive after two years 
suggested that cG250 might be able to modulate the natural course of mRCC. One group of patients 
received extended treatment (an additional eight weeks of treatment). These patients showed a median 
survival of 39 months, compared to 10 months in the discontinued group. Patients receiving extended 
treatment with cG250 showed a significantly longer survival rate than the nonresponsive patients (70% 
vs. 26%). The levels of mAbG250-mediated ADCC differed between the patients: 42% of the patients 
showed moderate ADCC (5%–25%), whereas in 33% of patients, no ADCC was demonstrated. There 
was no clear correlation between the in vitro levels of cytotoxicity and the clinical responses. In 
addition, no correlation between the proportion of NK cells and the level of mAbG250-mediated 
ADCC was observed. In this non-randomized setting, it has been difficult to evaluate the true effect of 
cG250 treatment on the disease course of patients, as the natural disease course of mRCC is highly 
variable and periods with SD and/or PR can occur, even in the absence of treatment.  
Based on these results, an adjuvant double-blind, placebo controlled phase 3 trial was started 
(ARISER, Adjuvant RENCAREX® Immunotherapy Phase III trial to study efficacy in non-metastatic 
RCC), aiming at reducing the recurrence of disease in nephrectomized RCC patients who have a  
high risk of relapse (http://www.wilex.de/portfolio-english/rencarex/phase-III-ariser/) [48]. The trial 
recruited 864 patients with prior nephrectomy of primary ccRCC; patients received a once-weekly 
infusion of RENCAREX® or placebo for 24 weeks. Those patients receiving the active drug received a 
loading dose of 50 mg in week 1 and weekly doses of 20 mg during weeks 2–24.  
Unfortunately, the trial did not meet its primary endpoint. The analysis showed no improvement in 
median DFS (approximately 72 months) following RENCAREX® treatment compared with placebo. 
However, preliminary results of a retrospective subanalysis appear to indicate that with increasing 
CAIX expression in tumor tissue, as quantified by a CAIX score, the treatment was more effective; 
DFS showed a clinically and statistically significant improvement in the patient population with a high 
CAIX level treated with cG250 compared to both placebo and patients with a low CAIX score (press 
release Wilex, 26 February, 2013). No other data are available at present. Therefore, an immunotherapy 
for ccRCC in the adjuvant setting might still be an option in a highly defined subpopulation. 
Since interleukin-2 (IL-2) has been known to enhance ADCC of mAbs, the combination of this 
cytokine with cG250 was evaluated. In vitro studies had demonstrated that cG250 ADCC was 
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increased when cells from IL-2-treated patients were used, suggesting that the combination of cG250 
with IL-2 might be superior to cG250 alone [55]. In a phase 2 trial, 35 patients with progressive mRCC 
received weekly intravenous infusions of 50 mg of cG250 and daily subcutaneous low-dose IL-2 for 
11 weeks. Treatment was well tolerated with little toxicity, attributable to IL-2. Clinical benefit was 
noted in eight of 35 patients (23%), with one long-lasting PR (>95 weeks), six long-lasting SD  
(>24 weeks) and a mean survival of 24 months, with 45% of the 30 evaluable patients still alive after 
two years. The extended treatment group (an additional six weeks of treatment) showed a median 
survival of 41 months, compared with 13 months in the non-response group. Patients receiving extended 
treatment showed a significantly longer survival rate than the non-response patients (55% vs. 25%). 
The increased survival (as compared to historic controls) was deemed to be cG250-related and not 
related to the IL-2, as a six-fold decrease of the normal IL-2 dose was used [50]. The favorable outcome 
might have been due to a synergistic effect of cG250 and IL-2, as was observed in the in vitro studies.  
The number of effector cells (CD3−/CD16+/CD56+) increased during treatment, but lytic capacity 
per cell did not increase and ADCC and clinical outcome did not correlate. Similar results were 
observed in the study performed by Davis et al. [49]. Yet again, because patients were not randomized, 
it is difficult to judge the value of this observation. A randomized trial is needed to determine the true 
effect of the IL-2/cG250 treatment. 
Based on in vitro observations that with the addition of Interferons (IFNs), G250/CAIX expression 
was upregulated and that with Interferon gamma (IFN-γ), ADCC of cG250 was enhanced, the effect of 
cG250 combined with IFN-α was studied [56,57].  
In a multicenter, open-label, prospective, single-arm phase I/II trial study, cG250 in combination 
with IFN-α 2a was studied in a total of 32 patients with stage IV progressive RCC [51]. Patients 
received 20 mg cG250 weekly for three months, combined with IFN-α 2a, three million international 
unit (MIU), three times per week, subcutaneously. Twenty six of 31 patients were evaluable for 
response to treatment. Two patients showed a PR and 14 patients SD in week 16. One patient 
experienced a PR for at least eight months, and nine patients had long durable disease stabilization 
(≥24 weeks). Clinical benefit was obtained in 42% (11/26) of the patients. The overall median survival 
was 30 months for the 31 patients treated with WX-G250 and IFNα, with 57% of patients still alive 
after two years. The patients receiving extended treatment showed a median survival of 45 months 
compared with 10 months in the non-extended group. Patients receiving extended treatment with 
cG250 showed a significantly longer survival rate than the non-response patients (79% vs. 30%). 
4. Future Prospects 
Clinical studies have now firmly established that cG250 adequately targets ccRCC. However, to 
prove that cG250 imaging can be used to guide clinical management, more evidence is needed. Thus 
far, patients for whom surgery was part of their clinical management have been studied, but the 
question whether watchful waiting can be applied in patients in whom no cG250 targeting is seen 
remains to be answered. As suggested by Divgi et al. [35], the role of cG250 imaging in influencing 
outcome would perhaps be best assessed in a clinical trial carried out in patients with small renal mass 
tumors and associated comorbidities.  
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Another issue that needs further study is choice of radionuclide for imaging purposes. As discussed, 
111In-cG250 SPECT may provide the same information as 124I-cG250 PET, but with the advantage that 
this can be produced as an off-the-shelf product that can be used on site. Alternatively, other 
radionuclides, such as 89Zr, might provide a useful alternative: it is similar with respect to its chemical 
characteristics, but is PET imageable. Although the adjuvant study in a group of high-risk patients did 
not reach it primary end-point, it is noteworthy to mention that in a subgroup analysis, patients with 
high CAIX expression as determined by IHC showed lower recurrence than patient negative or low in 
CAIX expression levels. Biomarker studies have demonstrated that CAIX staining correlates with 
survival, as well as with response to high dose IL-2 [58,59]. A cutoff of 85% CAIX staining provided 
the most accurate prediction of survival. Low CAIX (≤85%) staining was an independent poor 
prognostic factor for survival for patients with mRCC. For patients with nonmetastatic RCC and at 
high risk for progression, low CAIX predicted a worse outcome similar to patients with metastatic 
disease. Intriguingly, CAIX expression correlated with response to high dose IL-2: survival >5 years 
was only seen in high CAIX expressers [60,61]. It is tempting to speculate that high-dose IL-2 
treatment leads to expansion of CAIX-specific CTL, but characterization of 18 different TIL cultures 
suggested that anti-G250 reactivity is rare [13]. Patient stratification based on CAIX expression might 
lead to a (adjuvant) treatment strategy similar to, e.g., trastuzumab treatment of patients with breast 
cancer, where a very high correlation exists between HER2 expression and the success of trastuzumab, 
which targets HER2 [62].  
In summary, mAbG250 has shown remarkable targeting ability, and the main value of the antibody 
at present appears to be as diagnostic and, also, as a delivery vehicle for RIT.  
cG250 PET imaging holds great promise for the future, both in detecting localized and advanced 
disease, albeit that the radioisotope to use is still under investigation. In the near future, a clinical trial 
with PET tracer 89Zr-girentuximab will be initiated in our center, which will provide additional 
information about the use of girentuximab-based immunoPET in ccRCC. 
Clinical trials with unmodified cG250 suggest that treatment with cG250 can influence the  
disease course in mRCC patients. However, to validate whether cG250 treatment is of value, large, 
randomized trials are needed. 
Besides the usefulness in radioimmunodetection, girentuximab is a potent carrier for RIT in  
ccRCC. However, there are still several hurdles to overcome before girentuximab-based RIT can be 
implemented as a standard treatment. As previously mentioned, it is not clear which patients benefit 
most from RIT. Past results indicate that RIT is mainly suitable for treatment of small-volume disease 
or, possibly, as adjuvant treatment in selected cases, and more evidence regarding this topic is 
expected from the ongoing clinical trials with 90Y and 177Lu-labeled girentuximab in the upcoming 
years. Besides better patient selection in the future, advances in dosimetric analysis will presumably 
contribute to the improvement of RIT, as the trade-off between efficacy and toxicity can be better 
tailored to the individual patient. Lastly, an important deficit in our current knowledge is how to 
optimally combine girentuximab-based RIT with the current standard of care in metastatic ccRCC.  
CAIX has also been used as a target in gene therapy studies with modified autologous T-cells [63].  
In these studies, patients with advanced RCC were infused with escalating doses of T-cells genetically 
retargeted with a chimeric antibody receptor (CAR) directed towards carbonic anhydrase IX. Thus, the 
antigen-specific variable regions of mAbG250 (targeting to RCC) were linked to T-cell receptor 
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signaling chains, leading to CAIX targeting in an MHC-independent context. Liver toxicity was 
observed at the lowest cell dose, illustrating the potency of the modified T-cells. The liver toxicity 
could be prevented by pre-dosing with cG250 before administering modified T-cells [64]. Given that 
similar to mAb studies, the observed “on”-target toxicity could be prevented by blocking antigenic 
sites in off-tumor organs, higher T-cell doses might be possible. Although this is a very intriguing 
approach, patient recruitment has been very slow, and the final results are awaited. 
Finally, the clinical management of mRCC has changed significantly over the last few years. 
Implementation of various tyrosine kinase inhibitors and mTOR inhibitors has led to improved 
progression-free survival. However, therapy resistance is a major issue, and these therapies are 
directed against the tumor vasculature and not against the tumor cells. Combination of TKI and cG250 
might be beneficial: they attack different targets, and the combination might lead to synergistic effects. 
In a preclinical study, the biodistribution of cG250 was determined in TKI treated mice. TKI are 
known anti-angiogenic drugs, and thus, the accessibility of tumor cells is likely to be altered. In nude 
mice bearing human RCC xenografts treated orally with sunitinib, vandetanib or sorafenib, tumor 
uptake of cG250 decreased dramatically, and vascular density decreased considerably, as judged by 
various markers [65]. This is comparable to the TKI effects on tumors in patients: large central 
necrotic areas can develop in tumors when patients are treated with TKI. When treatment was stopped, 
robust neovascularization, mainly at the tumor periphery, became apparent. Consequently, cG250 
uptake recovered, albeit that cG250 uptake appeared to be restricted to the tumor periphery, where 
vigorous neovascularization was visible. This animal study demonstrated that simultaneous 
administration of TKI and mAb cG250 is unlikely to improve therapy outcome. This was also 
demonstrated in patients; a markedly decreased uptake of 111In-girentuximab after treatment with TKI 
sorafenib was observed [66]. Data from this study suggest that the effect of girentuximab-based RIT 
would be severely hampered if given during TKI treatment. However, the observation that shortly after 
discontinuation of TKI treatment, mAb accumulation was restored, suggested that sequential treatment 
strategies might be useful [65]. Because cG250 and TKI appear to be feasible in sequence only, studies 
were designed to determine the optimal interval between TKI treatment and cG250 administration. 
Biodistribution studies in two different animal models demonstrated that a 3D time interval was 
sufficient to reach optimal antibody accumulation (manuscript in preparation). Because TKI are also 
given in cycles in patients (four week treatment followed by two weeks off treatment), it appears that, 
indeed, combination of Sunitinib with mAb cG250 is feasible in mRCC patients, but the optimal 
treatment schedule needs to be determined.  
Anti-CAIX antibodies that combine inhibition of the enzymatic activity of CAIX with ADCC 
and/or CDC might be more potent than mAbG250, which does not inhibit the enzymatic activity of 
CAIX. Recently, a CAIX-specific antibody with an inhibitory effect on the carbonic anhydrase activity 
was described [67]. Up to 76% of CAIX activity was inhibited with the full-length IgG antibody 
MSC8. The authors speculated that combining target specificity with enzymatic inhibition in one 
antibody molecule may have an additive effect on reducing tumor growth. This interesting hypothesis 
will need to be substantiated.  
  




In summary, mAbG250 has shown outstanding targeting ability, and cG250 PET imaging holds 
great promise for the future, both in detecting localized and advanced disease, albeit that the most 
favorable radioisotope still needs to be determined. 
Confirmation of the results obtained in the non-randomized clinical trials with unmodified cG250 is 
needed to substantiate the value of cG250 treatment in mRCC. Girentuximab-based RIT hold promise 
for treatment of patients with small-volume disease or, possibly, as adjuvant treatment in selected 
cases, and ongoing clinical trials in the upcoming years should provide evidence for this assumption. 
Lastly, whether combination of girentuximab-based RIT with the current TKI is possible needs to  
be established. 
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